Kite Pharma is flying high with the addition of a new member to its senior leadership team. Brian Heath has joined Gilead Sciences’ cell therapy subsidiary as a senior vice president and head of ...

Sartorius Stedim Biotech SA / Key word (s): Dividend Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.69 euros per share to Annual Shareholders’ Meeting 07-Feb-2025 ...

WEST JEFFERSON, OHIO / ACCESS Newswire / January 30, 2025 / AmplifyBio, a leading preclinical CRO and CDMO played a pivotal ...

Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at ...

The Global Oncology Drug market was estimated at $227.2 billion in 2024 and is projected to reach $582.21 billion by 2034 , reflecting a robust CAGR of 11.67% over the forecast period from 2024 to ...

A California federal district court denied Gilead Sciences, Inc. and Kite Pharma, Inc.’s motion to dismiss unpaid overtime claims under the Fair Labor Standards Act by two cell therapy specialists ...

Kite, a Gilead Sciences company, will share four posters that add to the growing body of evidence to support the clinical use of its chimeric antigen receptor (CAR) T-cell therapy portfolio, at the ...

Kite Pharma’s share price has dived after it emerged that a patient has died from cerebral oedema while being treated with its CAR-T therapy, KTE-C19. Investors were spooked by the news ...

Gilead Sciences' cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging up to $2.3 billion for a partnership with Shoreline Bioscience focusing on off ...

The former Kite Pharma executive has identified stiff person syndrome (SPS), a rare autoimmune neurological disorder launched into public attention by Céline Dion’s diagnosis, as the initial ...

Shoreline Biosciences plans to let go of an undisclosed number of employees tied to a cell therapy project with Gilead Sciences’ Kite Pharma, Endpoints News reported this week. While Shoreline ...

Global Cell Therapy market is driven by increasing demand for advanced therapies in oncology, regenerative medicine, and immunology. The market's expansion is also fueled by continuous innovations in ...